DSIP
Also known as: Peptídeo Indutor de Sono Delta
Molecular Identifiers
Overview
Neuropeptide that regulates sleep and circadian rhythms. Induces delta wave sleep (deep sleep) without forced sedative effect. Acts on neuroendocrine modulation and possesses adaptogenic and antioxidant properties.
The interest in DSIP lies in the regulation of deep sleep: it induces the delta wave phase without the forced sedative effect typical of classical hypnotics, modulates circadian rhythms, and has adaptogenic and antioxidant properties. It is proposed in chronic insomnia, adrenergic stress, and as support for physical recovery, with effects also on neuroendocrine regulation (ACTH, cortisol, LH).
It has no approval as a medicine by the FDA, EMA, or ANVISA. In the peptide market it circulates through compounding pharmacies and specialized suppliers, in short cycles of 2-4 weeks, with subcutaneous administration 30-60 minutes before bedtime. The half-life is very short (~15-25 minutes), so the clinical effect appears to result from a signaling cascade rather than the sustained presence of the peptide.
It was characterized in the 1970s from research on rabbit blood during the delta phase of sleep, led by the Schoenenberger and Monnier group in Switzerland. Clinical evidence in humans is old and scarce, with most publications concentrated in the 1980s-90s.
WAGGDASGE Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu Half-life
~15-25 minutes
Administration Route
Subcutaneous or intravenous
Category
Cognitive & Neuroprotective
Mechanism of Action
- Induction of delta wave sleep (restorative deep sleep)
- Modulation of circadian rhythms and the sleep-wake cycle
- Neuroendocrine regulation (ACTH, cortisol, LH)
- Antioxidant and anti-stress properties
- Limitation of oxidative stress at the cellular level
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 100-300 mcg per subcutaneous injection |
| Frequency | Once daily |
| Timing | 30-60 minutes before bedtime |
| Duration | 2-4 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Daytime drowsiness
- Mild morning headache
- Dizziness
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of DSIP found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on DSIP.
Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke
Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, Slashcheva GA, Prudchenko IA, Mikhaleva II, Khokhlova ON, Murashev AN, Ivanov VT
Effects of Delta-Sleep-Inducing Peptide on 24-Hour Sleep-Wake Behaviour in Severe Chronic Insomnia
Schneider-Helmert D
Related Peptides
Adamax
100-500 mcg via intranasal or subcutaneous · 1-2 times daily
Cerebrolysin
5-30 ml per injection · Once daily
Cortagen
Dihexa
Epithalon
1-5 mg per subcutaneous injection (some protocols use 5-10 mg per full cycle) · Once daily or every other day
FG Loop
25-200 mg intranasal (single ascending dose Phase 1) · Single dose (tolerability study)